BioCardia (FRA:6JU0) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6JU0 BioCardia Inc FRA:6JU0
21 GF Score
Price €4.26
! 1 Warning Sign
View Full Analysis

What is BioCardia FFO?

FFO (Funds from operations) only applies to REITs.

FRA:6JU0
21GF Score
BioCardia Inc FRA:6JU0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCardia Business Description

Other Exchanges BCDA:USA
Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
21GF Score

Get the complete analysis for FRA:6JU0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.26
Price